论文部分内容阅读
目的 :评价氨曲南治疗老年下呼吸道细菌感染的疗效和安全性。方法 :老年人下呼吸道细菌感染 12 1例 ,随机分氨曲南组 6 0例 ,用氨曲南2 .0 g ,加入氯化钠注射液 10 0mL中 ,iv ,gtt ,q 12h ,疗程 7～ 14d ;头孢他啶组 6 1例 ,用头孢他啶2 .0 g,加入氯化钠注射液 10 0mL中 ,iv ,gtt ,q 12h ,疗程 7～ 14d。结果 :氨曲南组和头孢他啶组有效率分别为 83%和 80 % ,痊愈率分别为 5 8%和5 4% ,差异无显著意义 (P >0 .0 5 )。 2组细菌清除率分别为 85 %和 82 % ,细菌阴转率分别为 82 %和82 % ,差异无显著意义 (P >0 .0 5 ) ;2组不良反应发生率分别为 2 %和 3% ,实验室检查异常发生率分别为 3%和 3% ,均系轻度呈一过性 ,差异无显著意义 (P >0 .0 5 )。结论 :氨曲南治疗老年下呼吸道细菌感染的安全、有效
Objective: To evaluate the efficacy and safety of aztreonam in the treatment of lower respiratory tract bacterial infections in the elderly. Methods: A total of 121 elderly patients with lower respiratory tract bacterial infection were randomly divided into aztreonam group (60 cases), aztreonam 2 0 g, sodium chloride injection 10 0 mL, iv, gtt, q 12h, treatment 7 ~ 14d; ceftazidime group 61 cases, with ceftazidime 2.0 g, sodium chloride injection 10 0mL, iv, gtt, q 12h, treatment of 7 ~ 14d. Results: The efficiencies of aztreonam and ceftazidime were 83% and 80% respectively, and the cure rates were 58% and 54% respectively, with no significant difference (P> 0.05). The bacterial clearance rates of two groups were 85% and 82%, respectively, and the rates of bacterial negative conversion were 82% and 82%, respectively, with no significant difference (P> 0.05). The incidences of adverse reactions in the two groups were 2% and 3% %, Laboratory abnormalities were 3% and 3%, respectively, were mild transient, the difference was not significant (P> 0.05). Conclusion: Aztreonam is safe and effective in the treatment of lower respiratory tract bacterial infections in the elderly